Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 15Thoracic 6Breast 3Sarcoma 2Gynecologic 2Plasma cell 1Genitourinary 1CNS 1

Conditions

Ovarian Neoplasms 106Fallopian Tube Neoplasms 48Carcinoma, Ovarian Epithelial 31Uterine Cervical Neoplasms 28Pancreatic Neoplasms 13Endometrial Neoplasms 13Neoplasms 10Colorectal Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 10Recurrence 7Prostatic Neoplasms 7Neoplasm Metastasis 7Lung Neoplasms 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Sarcoma 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Peritoneal Neoplasms 5Cholangiocarcinoma 5Small Cell Lung Carcinoma 4Melanoma 4Head and Neck Neoplasms 4Esophageal Neoplasms 4Colonic Neoplasms 4Vulvar Neoplasms 3Uterine Neoplasms 3Multiple Myeloma 3Carcinoma 3

Interventions

Early Intervention, Educational 6Oxaliplatin 5Methods 4Cisplatin 4pembrolizumab 3Trastuzumab 3Surveys and Questionnaires 3Specimen Handling 3Leucovorin 3Fluorouracil 3Carboplatin 3X-Rays 2Radiotherapy 2Observation 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2Irinotecan 2Interleukin-12 Subunit p35 2Gemcitabine 2Cyclophosphamide 2Counseling 2Cetuximab 2Capecitabine 2Biopsy 2veliparib 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1sodium thiosulfate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Rectal Neoplasms × Gemcitabine × Gynecologic × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT02632448 2025-05-02

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Esperas Pharma Inc.

Phase 1/2 Completed
229 enrolled
BreastGastrointestinalGynecologicSarcoma

Breast Neoplasms, Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Recurrence, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡